13 completed, 2 unknown, 1 terminated. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 13, Unknown 2, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Migraine without Aura: new trials by email Literature Review of Migraine without Aura trials Research Report on Migraine without Aura
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Anisodine Hydrobromide, Anisodine Hydrobromide placebo - Migraine Without Aura, Migraine With Aura | Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 288 | 2023-10-30 | 2024-02-28 |
| TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME） Tizanidine Hydrochloride, Tizanidine Hydrochloride Placebo - Migraine Without Aura, Migraine With Aura | Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 189 | 2023-06-01 | 2024-08-01 |
| Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room Clorazepate Dipotassium, Placebo, Ketoprofen - Migraine, Migraine Without Aura | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 323 | 2021-07-08 | 2025-09-08 |
| A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine Dihydroergotamine, Placebo - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 1591 | 2021-06-30 | 2023-11-27 |
| A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Dihydroergotamine - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 482 | 2020-09-14 | 2023-07-03 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine Dihydroergotamine, Placebos - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 1201 | 2019-06-24 | 2023-06-29 |
| Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment Sumatriptan+Promethazine (SPr) - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 350 | 2013-01-01 | 2013-07-30 |
| Candesartan Versus Propranolol for Migraine Prevention Candesartan, propranolol, placebo - Migraine Without Aura, Migraine With Aura | Phase 2 / Phase 3 | Completed | Norwegian University of Science and Technology | 72 | 2009-04-01 | 2013-12-24 |
| Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Maxalt 10mg MLT plus Caffeine 75mg, Maxalt 10mg MLT plus Placebo, Placebo + Placebo - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Diamond Headache Clinic | 50 | 2007-04-01 | 2012-04-25 |
| TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) sumatriptan succinate / naproxen sodium, Placebo - Migraine, Without Aura | Phase 3 | Completed | GlaxoSmithKline | 679 | 2006-09-01 | 2016-12-16 |
| Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Laxymig ER (drug) - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Lotus Pharmaceutical | 74 | 2004-11-01 | 2007-09-10 |
| Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection - Migraine Without Aura Prophylaxis | Phase 3 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 128 | 2003-02-01 | 2019-02-18 |
| A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine topiramate, propranolol - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 786 | 2001-04-01 | 2010-11-19 |
| A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine topiramate - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 768 | 2001-03-01 | 2010-11-19 |
| A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine topiramate - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 763 | 2001-02-01 | 2010-11-17 |
| Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Placebo, Eletriptan HBr 40 mg, Eletriptan HBr 80 mg - Migraine Without Aura, Migraine With Aura | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 971 | 2000-03-01 | 2021-01-27 |
Migraine with Aura (14) · Migraine Disorders (12) · Headache (4)
Brain Diseases (16) · Central Nervous System Diseases (16) · Headache Disorders (16) · Headache Disorders, Primary (16) · Nervous System Diseases (16) · Migraine Disorders (4) · Neurologic Manifestations (4) · Pain (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4)
Dihydroergotamine (3) · Topiramate (3) · Propranolol (2) · Botulinum Toxins, Type A (1) · Caffeine (1) · Clorazepate Dipotassium (1) · Ketoprofen (1) · Metoclopramide (1) · Naproxen (1) · Pharmaceutical Preparations (1) · Sumatriptan (1) · abobotulinumtoxinA (1) · anisodine (1) · candesartan (1) · eletriptan (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Satsuma Pharmaceuticals, Inc. (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Assistance Publique - Hôpitaux de Paris (1) · Department of Medical Services Ministry of Public Health of Thailand (1) · Diamond Headache Clinic (1) · GlaxoSmithKline (1) · Lotus Pharmaceutical (1) · Norwegian University of Science and Technology (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Shahid Beheshti University of Medical Sciences (1)
United States (5) · China (2) · France (2) · Norway (2) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hungary (1) · Iran (1) · Italy (1) · Netherlands (1) · Portugal (1) · Spain (1)
Detlef Albrecht, MD (3) · Kaiming Liu, MD & PHD (2) · Frederick G Freitag, DO (1) · Lars J Stovner, Ph.D. (1) · Shuu-Jiun Wang, MD (1) · Siwaporn Chankrachang, MD (1)
PMID 22590713, PMID 23731663, PMID 24524844, PMID 30353868, PMID 30496104, PMID 30879893, PMID 32430657, PMID 14982912, PMID 15096395, PMID 15316798, PMID 23946318, PMID 24335848, PMID 39373843, PMID 41186275
2008 (1)